Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT03177499
Other study ID # CHESS1702
Secondary ID
Status Withdrawn
Phase N/A
First received
Last updated
Start date August 24, 2017
Est. completion date January 2019

Study information

Verified date January 2019
Source Nanfang Hospital of Southern Medical University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Portal pressure gradient (PPG) above 12 mmHg after transjugular intrahepatic portosystemic shunt (TIPS) increases the risk of portal hypertension complications. Currently, a PPG reduction <12 mmHg after TIPS is the most consistent threshold associated with almost complete protection from variceal bleeding and ascites. However, the measurement of PPG requires an invasive procedure. A recent study investigated the variations in PPG measurements collected at different time points after placement of TIPS and demonstrated that a time point of at least 24 hours after which PPG values were best maintained (early PPG). It is of great clinical value to propose that an immediate PPG measurement fail to accurately identify the risk of decompensated event. And early PPG would change the decision making for re-intervention or not. However, the repeated invasive examination is extremely difficult to follow in clinical practice worldwide. The prospective multicenter trial aims to assess the diagnostic performance of a virtual imaging-based early portal pressure gradient (vePPG) (investigational technology) from CT angiography and Doppler ultrasound with invasive early PPG measurement as reference. The study participants with portal hypertension will be prospectively recruited at 10 high-volume liver centers in China.


Description:

Portal pressure gradient (PPG) above 12 mmHg after transjugular intrahepatic portosystemic shunt (TIPS) increases the risk of portal hypertension complications. Currently, a PPG reduction <12 mmHg after TIPS is the most consistent threshold associated with almost complete protection from variceal bleeding and ascites. However, the measurement of PPG requires an invasive procedure. A recent study investigated the variations in PPG measurements collected at different time points after placement of TIPS and demonstrated that a time point of at least 24 hours after which PPG values were best maintained (early PPG). It is of great clinical value to propose that an immediate PPG measurement fail to accurately identify the risk of decompensated event. And early PPG would change the decision making for re-intervention or not. However, the repeated invasive examination is extremely difficult to follow in clinical practice worldwide. The prospective multicenter trial aims to assess the diagnostic performance of a virtual imaging-based early portal pressure gradient (vePPG) (investigational technology) from CT angiography and Doppler ultrasound with invasive early PPG measurement as reference. The study participants with portal hypertension will be prospectively recruited at 10 high-volume liver centers (Beijing Shijitan Hospital; 302 Hospital of PLA; Nanfang Hospital, Southern Medical University; The Third Xiangya Hospital of Central South University; Xingtai People's Hospital; Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University; First Affiliated Hospital, Sun Yat-Sen University; Beijing Ditan Hospital; PLA Army General Hospital; Third Affiliated Hospital, Sun Yat-Sen University) in China.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date January 2019
Est. primary completion date January 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

- Patients providing written informed consent

- Patients with portal hypertension and received the placement of TIPS

- Patients with invasive immediate PPG and early PPG measurement

- Has undergone > 64 multi-detector row CT angiography and Doppler ultrasound within 3 days prior to invasive early PPG measurement

Exclusion Criteria:

- Any severe adverse events after TIPS placement

- Inability to adhere to study procedures

- Prior devascularization operation

- Has received a liver transplant

- Patients with known anaphylactic allergy to iodinated contrast

- Pregnancy or unknown pregnancy status

- Patient requires an emergent procedure

- Any active, serious, life-threatening disease

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Invasive PPG
Invasive PPG obtained by means of catheterization.

Locations

Country Name City State
China 302 Hospital of PLA Beijing Beijing
China Beijing Ditan Hospital, Capital Medical University Beijing Beijing
China Beijing Shijitan Hospital, Capital Medical University Beijing Beijing
China PLA Army General Hospital Beijing Beijing
China The Third Xiangya Hospital of Central South University Changsha Hunan
China Nanfang Hospital, Southern Medical University Guangzhou Guangdong
China The First Affiliated Hospital of Sun Yat-sen University Guangzhou Guangdong
China The Third Affiliated Hospital of Sun Yat-Sen University Guangzhou Guangdong
China Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University Luzhou Sichuan
China Xingtai People's Hospital Xingtai Hebei

Sponsors (10)

Lead Sponsor Collaborator
Nanfang Hospital of Southern Medical University Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Beijing 302 Hospital, Beijing Ditan Hospital, Beijing Shijitan Hospital, First Affiliated Hospital, Sun Yat-Sen University, PLA Army General Hospital, The Third Xiangya Hospital of Central South University, Third Affiliated Hospital, Sun Yat-Sen University, Xingtai People's Hospital

Country where clinical trial is conducted

China, 

References & Publications (5)

de Franchis R; Baveno VI Faculty. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015 Sep;63(3):743-52. doi: 10.1016/j.jhep.2015.05.022. Epub 2015 Jun 3. — View Citation

Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology. 2017 Jan;65(1):310-335. doi: 10.1002/hep.28906. Epub 2016 Dec 1. Erratum in: Hepatology. 2017 Jul;66(1):304. — View Citation

Min JK, Leipsic J, Pencina MJ, Berman DS, Koo BK, van Mieghem C, Erglis A, Lin FY, Dunning AM, Apruzzese P, Budoff MJ, Cole JH, Jaffer FA, Leon MB, Malpeso J, Mancini GB, Park SJ, Schwartz RS, Shaw LJ, Mauri L. Diagnostic accuracy of fractional flow reserve from anatomic CT angiography. JAMA. 2012 Sep 26;308(12):1237-45. — View Citation

Qi X, Li Z, Huang J, Zhu Y, Liu H, Zhou F, Liu C, Xiao C, Dong J, Zhao Y, Xu M, Xing S, Xu W, Yang C. Virtual portal pressure gradient from anatomic CT angiography. Gut. 2015 Jun;64(6):1004-5. doi: 10.1136/gutjnl-2014-308543. Epub 2014 Nov 14. — View Citation

Silva-Junior G, Turon F, Baiges A, Cerda E, García-Criado Á, Blasi A, Torres F, Hernandez-Gea V, Bosch J, Garcia-Pagan JC. Timing Affects Measurement of Portal Pressure Gradient After Placement of Transjugular Intrahepatic Portosystemic Shunts in Patients With Portal Hypertension. Gastroenterology. 2017 May;152(6):1358-1365. doi: 10.1053/j.gastro.2017.01.011. Epub 2017 Jan 24. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary vePPG Numerical Correlation Correlation of vePPG numerical value with early PPG numerical value 1 day
Secondary Immediate PPG Numerical Correlation Correlation of immediate PPG numerical value with early PPG numerical value 7 days
Secondary Diagnostic Performance of vePPG Accuracy, sensitivity, specificity, positive predictive value and negative predictive value of vePPG to determine re-intervention or not when compared to invasive early PPG as reference (PPG=12mmHg) 1 day
See also
  Status Clinical Trial Phase
Recruiting NCT03713606 - Serum Biomarkers for Portal Hypertension in Cirrhosis (Pan-CHESS1802)
Recruiting NCT02505152 - Percutaneous Transhepatic Intrahepatic Portosystemic Shunt for Treatment of Portal Vein Occlusion With Symptomatic Portal Hypertension After Splenectomy N/A
Recruiting NCT02504034 - Interventional Radiology for the Treatment of Symptomatic Portal Hypertension in Patients With Cavernous Transformation of Portal Vein N/A
Completed NCT02669875 - Serelaxin To Lower Portal Pressure Phase 2
Recruiting NCT04720456 - SHAPE of Portal Hypertension in Children Phase 2
Completed NCT04645550 - Apixaban, Warfarin and Aspirin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy(ESAWAAPT) Phase 4
Recruiting NCT02305914 - Follow-up Study of Complications of Acute Pancreatitis N/A
Completed NCT01095185 - Efficacy of Statin Association With Standard Treatment in Prevention of Recurrent Hemorrhage in Patient With Cirrhosis and Variceal Bleeding Phase 3
Terminated NCT05282121 - A Study to Test Whether BI 685509 Alone or in Combination With Empagliflozin Helps People With Liver Cirrhosis Caused by Viral Hepatitis or Non-alcoholic Steatohepatitis (NASH) Who Have High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver) Phase 2
Completed NCT00004641 - A Study to Prevent Complications of High Blood Pressure Caused by Hepatitis in Patients With Cirrhosis Phase 2
Completed NCT03138915 - Radiomics Signature of Hepatic Venous Pressure Gradient (rHVPG) With CT Angiography (CHESS1701) N/A
Completed NCT03175731 - PPIs and Gastroesophageal Varices in Liver Cirrhosis (PPIs: Proton Pump Inhibitors) Phase 4
Active, not recruiting NCT04315571 - Comparing Ascites Relief In Two Standard Treatments: Large Volume Paracentesis Vs. Early Tips Using Viatorr Controlled Expansion Stents N/A
Completed NCT03459378 - Outcome After TIPS
Recruiting NCT03470389 - Establishment and Assessment of the HVPG Using Biofluid Mechanics (HVPGBFM) N/A
Completed NCT02462967 - Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis Phase 2
Active, not recruiting NCT01097811 - Comparison Between Erythromycin and Neomycin Treatment of Hepatic Encephalopathy N/A
Terminated NCT06082843 - A Study to Test Whether Avenciguat Helps People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver) Who Had Bleeding in the Esophagus or Fluid Accumulation in the Belly Phase 2
Recruiting NCT03315767 - Spleen-ARFI-assisted-Portal-Hypertension-Evaluation-Study (SAPHES) N/A
Terminated NCT05161481 - A Study to Test Whether Two Different Doses of Avenciguat Help People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Live Phase 2